Chimovits Erez
SEC Form 4 insider trading activity
Chimovits Erez has filed 2 SEC Form 4 filings (8 transaction rows) across 2 companies, including ADRX, BRVE, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Sep 30, 2026.
On the most recent filing, Chimovits Erez is listed as Director at ADARx Pharmaceuticals, Inc. Inside the rolling window, Chimovits Erez reported 2 open-market purchases totaling $36.0M in ADRX and BRVE and no open-market sales. The largest disclosed transaction in the window is a purchase of 1,940,000 BRVE shares on Aug 7, 2026, worth $34.9M.
Companies traded
Other insiders at ADRX
Insider Buying
$36.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Chimovits Erez made?
Chimovits Erez has filed 2 SEC Form 4 filings (8 transaction rows) across 2 companies, including ADRX, BRVE since 2026.
Which companies does Chimovits Erez trade?
Chimovits Erez has filed SEC Form 4 disclosures for 2 companies, including ADRX, BRVE.
When was Chimovits Erez's most recent SEC Form 4 filing?
Chimovits Erez's most recent SEC Form 4 filing on Tracefour is dated Sep 30, 2026.
What is Chimovits Erez's total buy and sell value in the current window?
Inside the rolling retention window, Chimovits Erez bought $36.0M and sold $0 based on SEC Form 4 filings.
What was Chimovits Erez's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 1,940,000 BRVE shares on 2026-08-07, worth $34.9M, per SEC Form 4 filings.